tbuckley/cabot-search huggingface dataset:
Acute Stress Response and Posttraumatic Stress Disorder in Traffic Accident Victims: A One-Year Prospective, Follow-Up Study
Authors: Danny Koren, Isaac Arnon, Ehud Klein
Journal: American Journal of Psychiatry (1999)

This study was designed to assess the natural course of posttraumatic symptoms formation, as well as the degree to which acute stress reactions predict later posttraumatic stress disorder (PTSD) in injured traffic accident victims.A prospective, 1-year follow-up study was carried out on 74 injured traffic accident victims and a comparison group of 19 patients who were hospitalized for elective orthopedic surgery. Participants were interviewed within the first week following the accident, and follow-up interviews were performed 1, 3, 6, and 12 months after the accident. At 12 months, a structured clinical interview was administered to determine a formal DSM-III-R diagnosis of PTSD.Twenty-four (32%) of the 74 traffic accident victims, but none of the 19 comparison subjects, met DSM-III-R criteria for PTSD at 1 year. Traffic accident victims who developed PTSD had higher levels of premorbid and comorbid psychopathology. Levels of posttraumatic symptoms were significantly higher from the outset in the subjects who developed PTSD and worsened progressively over the first 3 months, in contrast to subjects without PTSD, who manifested gradual amelioration of symptoms during this time. Existence of posttraumatic symptoms immediately after the accident was a better predictor of later PTSD than was accident or injury severity.In this study, a significant portion of injured traffic accident victims manifested PTSD 1 year after the event. The development of PTSD at 1 year can be predicted as early as 1 week after the accident on the basis of the existence and severity of early PTSD-related symptoms. However, the first 3 months following the accident appear to be the critical period for the development of PTSD.
Differential effects of colchicine in blood mononuclear cells of patients with Behçet disease in relation to colchicine responsiveness
Authors: M.Y. Woo, O. Cho, M.J. Lee, K. Kim, E.S. Lee, S. Park
Journal: British Journal of Dermatology (2012)

Journal Article Differential effects of colchicine in blood mononuclear cells of patients with Behçet disease in relation to colchicine responsiveness Get access M.Y. Woo, M.Y. Woo Department of MicrobiologyGraduate Program of Molecular Medicine Search for other works by this author on: Oxford Academic Google Scholar O. Cho, O. Cho Department of Microbiology Search for other works by this author on: Oxford Academic Google Scholar M.J. Lee, M.J. Lee Department of Microbiology Sun Park or Eun‐So Lee. E‐mail: sinsun@ajou.ac.kr or esl@ajou.ac.kr Search for other works by this author on: Oxford Academic Google Scholar K. Kim, K. Kim Department of Microbiology Search for other works by this author on: Oxford Academic Google Scholar E.S. Lee, E.S. Lee Department of Dermatology, Ajou University School of Medicine, Youngtongku Wonchondong San 5, Suwon 442‐749, Korea Search for other works by this author on: Oxford Academic Google Scholar S. Park S. Park Department of Microbiology Sun Park or Eun‐So Lee. E‐mail: sinsun@ajou.ac.kr or esl@ajou.ac.kr Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 167, Issue 4, 1 October 2012, Pages 914–921, https://doi.org/10.1111/j.1365-2133.2012.11067.x Published: 01 October 2012 Article history Accepted: 16 May 2012 Published: 01 October 2012
Cell/Molecular Biology Posters
Authors: P.M. McPherson, P.E. Ross, P.W. Dettmar
Journal: Gut (2001)

There was no significant change in systemic haemodynamics, bilirubin, albumin, INR or creatinine in either group.Conclusion: Anti-TNF therapy with thalidomide eVectively reduces portal pressure and hepatic vascular resistance supporting a role for TNF in the pathogenesis of human portal hypertension.
Neuropsychological Deficits in Adolescent-Onset Schizophrenia Compared With Attention Deficit Hyperactivity Disorder
Authors: Merete Øie, Bjørn Rishovd Rund
Journal: American Journal of Psychiatry (1999)

Impaired neuropsychological performance involving abstraction-flexibility, memory, motor function, and attention has frequently been reported in schizophrenia as well as in attention deficit hyperactivity disorder (ADHD). This study represents an attempt to compare groups of adolescents with schizophrenia and ADHD on a comprehensive neuropsychological test battery. Such a comparison affords the opportunity to ascertain differences in the degree, profile, and specificity of impairments.The performance of 19 adolescents with schizophrenia, 20 adolescents with ADHD, and 30 normal adolescents on a broad battery of cognitive tests was compared.The schizophrenic group showed the most pronounced deficits on tests of abstraction, visual memory, and motor function in comparison with the subjects with ADHD, while the ADHD subjects had the most pronounced deficits on measures of attention, verbal memory, and learning.The subjects with schizophrenia appeared to have a more general pattern of brain dysfunction, whereas the impairment of the ADHD subjects seemed to be relatively specific to tests associated with frontal lobe function.
Abstract 12470: Defining Patent Foramen Ovale Anatomy and Morphological Phenotypes Using Three-Dimensional Transoesophageal Echocardiography: A Practical Approach
Authors: Anna C Kydd, Patrick A Calvert, Preety Das, Len M Shapiro, Bushra S Rana
Journal: Circulation (2011)

Background  Three dimensional transoesophageal echocardiography (3D TEE) has allowed better understanding of atrial septal anatomy and patent foramen ovale (PFO) morphology. Anatomical variations seen in patients undergoing transcatheter device closure may influence device choice and procedural success. A practical approach to define and quantify salient features of more complex anatomical characteristics, by 3D echocardiography, has been suggested. How frequently these features occur is not known.   Methods  PFO morphology was assessed using full 3D TEE datasets available for 37 patients, with otherwise structurally normal hearts, undergoing transcatheter PFO closure at our institution from July 2009 to January 2011. Datasets obtained using a Philips iE33 ultrasound system were analysed either on or offline (QLab 3DQ, Philips Healthcare). PFO9s were grouped into simple or complex according to anatomical characteristics. Complex defects were defined as: long tunnel length >8mm, multiple openings into the left atrium, atrial septal aneurysm (septal sway >10mm), hybrid defect (additional small defect(s) in fossa ovalis), thick secundum septum (>8mm), Eustachian ridge (ER), Eustachian valve or Chiari network.   Results  92% of patients (n=34) had features of a complex PFO.76% of patients had a ER (n=28). 20 patients had a Eustachian valve and or a Chiari network. Median tunnel length was 5mm ( 8mm. 11% (n=4) patients had an atrial septal aneurysm, median septal sway 5mm (1-12mm). 19% (n=7) of PFO9s were hybrid defects and 4 patients had more that one opening into the left atrium. 2 of the patients had a significantly thickened secundum septum >8mm, median thickness was 4.9mm (0-8.9mm). Follow up bubble study data was available for 19 of the 37 patients (at 6-12 months), 2 patients had residual shunts. There was no association with any particular anatomic feature.   Conclusion  3D echo allows a practical qualitative and quantitative assessment of PFO anatomy and morphology. A detailed understanding of the complex variation in anatomy is crucial to guide device selection and to achieve successful percutaneous closure.
Vesicular Synaptobrevin/VAMP2 Levels Guarded by AP180 Control Efficient Neurotransmission
Authors: Seong Joo Koo, Gaga Kochlamazashvili, Benjamin Rost, Dmytro Puchkov, Niclas Gimber, Martin Lehmann, Georgi Tadeus, Jan Schmoranzer, Christian Rosenmund, Volker Haucke, Tanja Maritzen
Journal: Neuron (2015)
Biophysical and Bioassay Studies on Milk Fractions of Genetically Similar Agent-Bearing and Agent-Free Mouse Substrains&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: William T. Hall, William F. Feller
Journal: JNCI Journal of the National Cancer Institute (1967)

Samples of skim milk from 5 mouse strains and substrains (C3H, C3HfB, BALB/c, BALB/cfC3H, BALB/cf wild) were placed on Ficoll density gradients and centrifuged in a Splnee SW39 rotor at 37,000 rpm for 5 hours. The tubes were then arbitrarily divided into quarters, from which samples were taken for bioassay and electron microscopy. Milk from high-tumor-strain mice (C3H, BALB/cf wild, and BALB/cfC3H) contained a dense light-scattering zone, which was absent or greatly diminished in the low-tumor strains (C3HfB, BALB/c), composed of concentrated mammary-tumor virus particles. The zone of high virus-particle concentration in C3H and BALB/cf wild gave positive bioassay (nodule test) at a dilution of 10−5, while the corresponding zone in BALB/c and C3HfB milk was completely negative. Although there is not an absolute correspondence between strain tumor incidence and particle quantity in the milk, nonetheless, high-tumor-strain mice have many more particles than their syngeneic low-tumor-strain counterparts. The 100–110 mµ mammary tumor virions assume a much denser appearance following glutaraldehyde. chrome-osmium fixation than after fixation with chrome-osmium alone.
Markers of liver dysfunction in patients with obstructive sleep apnea
Authors: Maria Buttacavoli, Anna Maria Marotta, Alessandra Castrogiovanni, Carmela Giordano, Vincenzo Bellia, Maria Rosaria Bonsignore
Journal: European Respiratory Journal (2011)

Increased serum levels of liver enzymes have been reported in patients with obstructive sleep apnea (OSA), but the prevalence of liver dysfunction in OSA is poorly defined. In 91 consecutive patients (23 females) without serological evidence of viral hepatitis or alcohol-induced liver disease who underwent nocturnal respiratory monitoring for diagnosis of OSA, we measured alanine (ALT) and aspartate (AST) aminotransferase, and gamma-glutamyltransferase (GGT) in serum, together with the HOMA Index and the lipid profile. Mean age and BMI were 55±14 (SD) yr, and 37.4±8.4 kg/m 2 , respectively. OSA was moderate to severe (mean AHI 49±24/h, lowest SaO 2  69.3±12.8%). Increased ALT or AST (≥41 IU/L) was found in 11 and 5 patients (12% and 5.5%), respectively. Compared to patients with normal ALT levels, patients with elevated ALT were significantly younger (43.2±5.5 vs 56.4±14.3 yr, p  Funding by Italian Ministry of University and Research (PRIN 200895H8S9)
High F-18 FDG Uptake in a Paraspinal Textiloma
Authors: DE WINTER FREDERIC, HUYSSE WOUTER, PAEPE De PASCALE, LAMBERT BIEKE,, POFFYN BART, DIERCKX RUDI
Journal: Clinical Nuclear Medicine (2002)

FREDERIC, DE WINTER M.D.; WOUTER, HUYSSE M.D.; PASCALE, PAEPE De M.D.; BIEKE,, LAMBERT; BART, POFFYN M.D.; RUDI, DIERCKX M.D. P h.D. Author Information
Formoterol, but not indacaterol, induces transient hypoxemia in severe COPD
Authors: Roberto W. Dal Negro, Paola Pescatori, Claudio Micheletto, Silvia Tognella
Journal: European Respiratory Journal (2011)

β 2 -agonists are effective options in COPD. Mainly the short-acting compounds can rapidly induce a transient hypoxemia by affecting pulmonary vasculature. Most recent long-acting β 2 -agonists (LABA) were poorly investigated from this point of view.   Aim:  Aim was to measure and compare the hypoxemic effect of Formoterol (F) and Indacaterol (I) in moderate-to-severe COPD.   Methods:  24 ex-smoker patients (18m; mean age= 70.3y±6.1sd; range 51-76; mean FEV1/FVC = 52.2% pred. ±9.0sd; mean FEV1= 50.0±11.8ds) were studied after their written informed consent according to a double-blind, double-dummy, cross-over, randomized design. Active drugs were F 12mcg and I 300mcg, assumed in two different days, with a 36h-interval in between. Arterial blood was drawn in baseline; after 59, and 309 from F and I; FEV1 was measured at the same times.  Statistics:  Friedman9s analysis of variance by ranks and Page9s test for trend, and p   Results:  See Table 1 (means ± sd).   Discussion:  Both F and I induced rapidly an equal (p=ns) and significant (p 2  changes were significantly different with the two drugs (p   Conclusions:  1) the safety of I is emphasized; 2) the peculiar chemical structure of I and the fact that it behaves as a nearly full β 2 -adrenoceptor agonist likely contribute to explain its uneffectiveness in terms of β 2 -induced hypoxemia in COPD.
Preliminary observations on clotting under three hydrocolloid dressings
Authors: G D Mulder, A Walker
Journal: Journal of the Royal Society of Medicine (1989)

Four patients with five wounds were randomly assigned to treatment with three occlusive dressings: DuoDERM®, Restore® and Comfeel Ulcus®; the dressings were left intact for 24-48 h. When the dressings were removed, it was found that wounds that had been covered with Restore and Comfeel contained coagulated sanguinous material. Two wounds that had been covered with Comfeel and Restore, respectively, were then covered with DuoDERM, while one wound previously covered with DuoDERM was covered with Restore. Either no clotting occurred under DuoDERM or clots may have resolved. Although these preliminary data suggest that DuoDERM gel may have fibrinolytic properties, more extensive and controlled studies are needed to assess the characteristics of this dressing.
Specific Immunofluorescence Test for the Herpes-Type EB Virus of Burkitt Lymphoblasts, Authenticated by Electron Microscopy&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: M. A. Epstein, B. G. Achong
Journal: JNCI Journal of the National Cancer Institute (1968)
P65 Failure to control hepatitis B virus replication despite control of human immunodeficiency virus replication in co-infected patients on tenofovir-containing ART regimen cause for concern in hepatitis B virus monoinfection?
Authors: D Joshi, K Childs, I Carey, M Bruce, M Al-Freah, M Horner, P Harrison, A Suddle, K Agarwal, C Taylor
Journal: Gut (2010)

Introduction  Cross-resistance between human immunodeficiency virus (HIV) and hepatitis B virus (HBV) can play an important role in failure to control HBV replication in co-infected individuals resulting in suboptimal control of HBV. Tenofovir (TDF) based therapy should be effective for suppression of both HIV and HBV replication.  Aim  To evaluate HBV factors in HBV/HIV co-infected subjects with undetectable HIV and persistently detectable HBV following 48 weeks of TDF based anti-retroviral therapy (ART).  Method  Our prospectively maintained clinical database was interrogated. 113 HIV/HBV coinfected patients were identified; 14 (12.4%) patients had detectable HBV DNA (but undetectable HIV RNA) after 48 weeks of TDF based ART. 8/14 (57%) were eAg +ve, 12 patients were male, median age was 44.2 (39.9, 48.8) yrs. Direct sequencing of HBV polymerase was performed at baseline and 48 weeks. HBV DNA (log 10  IU/ml) testing with Roche Cobas Ampliprep/Taqman v2 (LL  Results  Baseline median HBV DNA was 7.74 (5.1, 8.0) log 10  IU/ml. HBV genotype was A in 7/14 (50%), E in 4 (29%), G in 2 (14%) and D in 1 pt. 9 pts (64%) had lamivudine (3TC) monotherapy for a median of 19.9 (8.3, 60.5) months prior to switching to a TDF regime; 3/9 pts also had a period of TDF monotherapy. All 14 patients received combination therapy of TDF and 3TC/FTC. At baseline 5/14 (36%) had evidence of 3TC resistance as shown by the M204V mutation alone or with L180M and/or V173L. 9/14 had no known mutations; no pt displayed TDF resistance. After 48 weeks of TDF based therapy HBV DNA was 1.95 (1.6, 3.2) log 10  IU/ml, in 8/14 pts HBV DNA was  10  IU/ml. HBV DNA became undetectable in 9/14 pts (64%) after median 175 weeks of therapy but 5/14 pts (36%) still had detectable HBV DNA a median of 199 weeks after TDF was started. At resistance testing after 48 weeks TDF: 8/14 pts had HBV DNA below limit of amplification, in 6/14 pts 2 showed persistent 3TC mutations, 1 pt showed wild type despite previous 3TC resistance and 3 showed no known mutations. No patient developed the A194T mutation conferring TDF resistance.  Conclusion  Despite optimal adherence to TDF treatment, as evidenced by control of HIV, 14 pts failed to achieve undetectable HBV DNA after 48 weeks of treatment. In 5/14 pts, HBV DNA remained detectable at a low level nearly 4 years into TDF treatment, but no patient developed TDF HBV resistance. The long-term clinical significance of low level HBV viraemia in this population is unclear. This may be an HIV specific issue or reflect cumulative HBV resistance allowing replication fitness. Further investigation by phenotypic analysis and/or ultra-deep pyrosequencing is warranted.
Expression of heat shock proteins in chronic obstructive pulmonary disease, vernal keratoconjunctivitis and ulcerative colitis
Authors: Paola Brun, Andrea Leonardi, Elena Tarricone, Davide Vallese, Bruno Balbi, Francesco Cappello, Antonino Di Stefano
Journal: European Respiratory Journal (2013)

Background and Aim : Inflammatory response in different organs share many similarities, but site-specific signs. The aim of the study was to compare heat shock proteins (HSPs) levels and expression in chronic obstructive pulmonary disease (COPD) to other inflammatory states, such as vernal keratoconjunctivitis (VKC), a recurrent ocular inflammatory disease, and ulcerative colitis (UC), an inflammatory bowel disease in which autoimune aggression may have a pathogenetic role.

Methods: 

We examined bronchial mucosal biopsies from COPD patients, conjunctival biopsies from VKC patients, and colon mucosa biopsies from patients with UC; age-matched controls were selected for each group. We evaluated levels (by immunohistochemistry) and expression (by RT-PCR) of Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90, and the main heat shock transcription factor HSF-1 and pHSF-1.

RESULTS: 

Hsp10 levels and expression increased in all pathological conditions, Hsp27 in VKC, Hsp40 in COPD and VKC, Hsp60 in COPD and UC, Hsp70 in UC and Hsp90 in VKC and UC, compared to controls. pHSF-1+ cells were significantly increased in COPD compared to controls, while was unaltered in VKC. All pathological tissues showed increased levels of macrophages (CD68) in lamina propria; COPD tissues were also all positive for neutrophils and VKC for eosinophils markers. Finally, Hsp60 co-localize with elastase positive cells in COPD and with CD68 positive cells in UC.

CONCLUSION: 

These results indicate that Hsps levels and expression change during these different inflammatory states. Further studies will prove the HSPs active involvement in triggering and/or maintaining of this inflammatory status.
A case series of CPAP therapy – Who declines treatment?
Authors: Stephanie Hobbins, Amina Mohamed, Michael Lang, Nazim Nathani
Journal: European Respiratory Journal (2014)

Introduction

Our department initiates approx. 600 patients on CPAP annually through 3 sleep clinics and historically has an acceptance rate of 75%. We wanted to identify common patient factors in the withdrawal group with a view to improving acceptance.

Method

Patient characteristics and polysomnography data of individuals attending 1 sleep clinic over a 2year period who withdrew CPAP therapy were retrospectively reviewed.

Results

48 patients were identified with mean BMI 34.25 and AHI 25.19. 67% of all patients were referred with predominantly snoring symptoms. Of the CPAP failures, 14 declined trial with no clear reason. 2 had surgical intervention and 5 did not start therapy. Of the patients who withdrew after initiation (n=27), 5 also had significant nocturnal hypoxia and hypoventilation.

View this table:

Polysomnography data for patients failing CPAP therapy





Common reasons for withdrawing were intolerance due to anxiety, claustrophobia or cough.

Conclusion

This review does not reveal specific characteristics although patients with snoring rather than somnolence predominant OSA may be less motivated to accept treatment. CPAP failures tended to have lower Epworth scores and so may underestimate the significance of their condition.

Patients with OHS are a distinct group who we need to persevere with bilevel ventilation with or without oxygen. Options for OSA patients include inpatient retrial, bilevel ventilation or non-benzodiazepine sedation with reintroduction of CPAP. Whether these measures would be successful or cost effective awaits evaluation.
Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q
Authors: Michael Heuser, Manja Meggendorfer, Michelle Maria Araujo Cruz, Larissa Koehler, Gudrun Goehring, Christina Ganster, Annika Gutermuth, Victoria Panagiota, Jana Fabisch, Claudia Haferlach, Christian Koenecke, Uwe Platzbecker, Christian Thiede, Ulrich Germing, Thomas Schroeder, Guido Kobbe, Steve Ehrlich, Kathrin Stamer, Brigitte Schlegelberger, Nicolaus Kröger, Arnold Ganser, Detlef Haase, Torsten Haferlach, Felicitas Thol
Journal: Blood (2014)
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Authors: A A Miller, J E Herndon, D R Hollis, J Ellerton, A Langleben, F Richards, M R Green
Journal: Journal of Clinical Oncology (1995)

PURPOSE This was a randomized phase III study to test the schedule dependency of etoposide given as a conventional 3-day intravenous (IV) regimen versus a prolonged 21-day oral regimen for extensive-stage small-cell lung cancer (SCLC). Both regimens contained IV cisplatin. The objectives were to compare survival (primary end point) and to establish response rates, failure-free survival, and toxicity (secondary end points). PATIENTS AND METHODS Patients with untreated measurable or assessable disease and normal organ function were eligible. Randomization was stratified according to performance status 0 versus 1 or 2. Treatment consisted of etoposide 130 mg/m2/d IV for 3 days and cisplatin 25 mg/m2/d IV for 3 days every 21 days for eight courses (schedule 1) versus etoposide 50 mg/m2/d orally for 21 days and cisplatin 33 mg/m2/d IV for 3 days every 28 days for six courses (schedule 2). In 1990, bioavailability of oral etoposide was assumed to be 50%, and the study was designed to deliver the same total doses of etoposide and cisplatin on both regimens over 24 weeks without the use of growth factors. RESULTS Between December 1990 and October 1993, 306 eligible patients were entered. Of these, 69% were male and 66% were &gt; or = 60 years of age; 21% had a performance status of 0, 47% a performance status of 1, and 32% a performance status of 2; 156 were randomized to receive schedule 1 and 150 to receive schedule 2. Overall median survival estimates were 9.5 and 9.9 months (difference not significant) for schedule 1 and schedule 2, respectively. The 95% confidence interval (CI) for overall survival, 8 to 11 months, was the same for both schedules, with 126 and 117 deaths on schedule 1 and 2, respectively. Both schedules also resulted in the same median failure-free survival estimate of 7 months (95% CI, 6 to 8 months on either schedule). Complete and partial responses were observed in 15% and 42% of patients on schedule 1 and 14% and 47% on schedule 2, respectively. The overall maximal hematologic toxicities grade 3 and 4 for leukocytes, neutrophils, platelets, and hemoglobin were, respectively, as follows: schedule 1, 62%, 85%, 32%, and 32%; schedule 2, 83%, 83%, 52%, and 53%. Lethal toxicity due to neutropenia and infection occurred in 4% of patients on schedule 1 and 10% on schedule 2 (difference not statistically significant). CONCLUSION The two schedules of etoposide in combination with cisplatin did not result in differences in treatment outcome with respect to tumor response and survival. However, a significantly greater rate of severe or life-threatening hematologic toxicity was noted on the 21-day oral etoposide treatment schedule.